Swords, R T <br/><br/>
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.  [electronic resource] 

 -  Blood cancer journal  02 2017 
 - e520 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2044-5385 
<br/><br/><label>Standard No.: </label>10.1038/bcj.2017.1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Cyclopentanes--administration & dosage<br/>Enzyme Inhibitors--administration & dosage<br/>Female<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>NEDD8 Protein--antagonists & inhibitors<br/>Pyrimidines--administration & dosage<br/>Young Adult